Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
1,983
Views
1
CrossRef citations to date
0
Altmetric
Neurology
Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden
Carlos Acostaa Value & Market Access, Biogen International GmbH, Baar, SwitzerlandCorrespondence[email protected]
https://orcid.org/0000-0002-7257-8675
Mattia Gianinazzia Value & Market Access, Biogen International GmbH, Baar, Switzerland
, Thibaut Dorta Value & Market Access, Biogen International GmbH, Baar, Switzerland
, Nigel Armstrongb Kleijnen Systematic Reviews, Ltd., York, UK
, Steve Ryderb Kleijnen Systematic Reviews, Ltd., York, UK
, Thomas Lundqvistc Market Access, Biogen Sweden AB, Upplands Väsby, Sweden
, Mats Ekelundc Market Access, Biogen Sweden AB, Upplands Väsby, Sweden
& Jan Lycked Institute of Neuroscience and Physiology, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
show all
Pages 770-780
|
Received 22 Feb 2021, Accepted 06 May 2021, Published online: 21 Jun 2021
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.